Concise review: current status of stem cells and regenerative medicine in lung biology and diseases.
Concise review: current status of stem cells and regenerative medicine in lung biology and diseases.
复制标题
DOI：
10.1002/stem.1506
复制
发表时间：
2014-01
期刊：
影响因子：
5.2
通讯作者：
Weiss, Daniel J.
中科院分区：
文献类型：
--
作者：
Weiss, Daniel J.
关键词：
肺部疾病仍然是全世界发病率和死亡率的重要和破坏性原因。与许多其他重大疾病相比，肺部疾病，特别是慢性阻塞性肺疾病(COPD)，包括哮喘和肺气肿，患病率正在上升，预计到2020年，COPD将成为全球第三大疾病死亡原因。迫切需要新的治疗选择。越来越多的干细胞和细胞疗法在肺生物学和疾病以及体外肺生物工程中的研究为增进肺生物学知识提供了令人兴奋的新途径，并为肺部疾病提供了新的潜在治疗方法。这些初步观察导致在肺动脉高压和慢性阻塞性肺疾病(COPD)的临床试验中对内皮祖细胞和间充质干细胞(基质细胞)的探索越来越多，并计划进行其他临床研究。利用具有生物合成结构和脱细胞组织的气管、喉、横隔膜和肺本身的体外生物工程已被用于探索肺的呼吸道和血管系统的工程。因此，肺是各种细胞治疗和再生医学方法的成熟器官。将介绍上述每个领域的当前最新进展，以及对当前考虑的基于细胞疗法的肺部疾病临床试验的讨论。
Lung diseases remain a significant and devastating cause of morbidity and mortality worldwide. In contrast to many other major diseases, lung diseases notably chronic obstructive pulmonary diseases (COPD), including both asthma and emphysema, are increasing in prevalence and COPD is expected to become the 3rd leading cause of disease mortality worldwide by 2020. New therapeutic options are desperately needed. A rapidly growing number of investigations of stem cells and cell therapies in lung biology and diseases as well as in ex vivo lung bioengineering have offered exciting new avenues for advancing knowledge of lung biology as well as providing novel potential therapeutic approaches for lung diseases. These initial observations have led to a growing exploration of endothelial progenitor cells and mesenchymal stem (stromal) cells in clinical trials of pulmonary hypertension and chronic obstructive pulmonary disease (COPD) with other clinical investigations planned. Ex vivo bioengineering of the trachea, larynx, diaphragm, and the lung itself with both biosynthetic constructs as well as decellularized tissues have been utilized to explore engineering both airway and vascular systems of the lung. Lung is thus a ripe organ for a variety of cell therapy and regenerative medicine approaches. Current state-of-the-art progress for each of the above areas will be presented as will discussion of current considerations for cell therapy based clinical trials in lung diseases.
登录
查看更多内容
影响因子：
11.2
作者：
Dome, Balazs;Timar, Jozsef;Tovari, Jozsef
通讯作者：
Tovari, Jozsef
DOI：
10.1164/rccm.200812-1949oc
发表时间：
2009-09-15
影响因子：
24.7
作者：
Borghesi, Alessandro;Massa, Margherita;Stronati, Mauro
通讯作者：
Stronati, Mauro
影响因子：
38.9
作者：
Cribbs, Sushma K.;Sutcliffe, Diane J.;Taylor, William R.;Rojas, Mauricio;Easley, Kirk A.;Tang, Li;Brigham, Kenneth L.;Martin, Greg S.
通讯作者：
Martin, Greg S.
影响因子：
8.8
作者：
Araujo, Indianara M.;Abreu, Soraia C.;Rocco, Patricia R. M.
通讯作者：
Rocco, Patricia R. M.
影响因子：
15.9
作者：
Chapman, Harold A.;Li, Xiaopeng;Vu, Thiennu H.
通讯作者：
Vu, Thiennu H.